Key result
BIOMArCS 2 trial tests intensive versus conventional glucose management to assess infarct size in ACS.
Why the study?
Does intensive glucose level control reduce infarct size in patients with acute coronary syndrome and admission hyperglycemia?
RCT (n=300)
1:1
Yes
Does intensive glucose level control reduce infarct size in patients with acute coronary syndrome and admission hyperglycemia?
The BIOMArCS 2 glucose trial is designed to evaluate whether intensive glucose management reduces infarct size in patients with acute coronary syndrome and admission hyperglycemia.
Authors
No takes yet. Share an insight, caveat, or question.
Remains unanswered whether intensive glucose control reduces infarct size in hyperglycemic ACS; BIOMArCS 2 will deliver randomized evidence.
Mulder et al. (2011) conducted an RCT in Acute coronary syndrome (n=300). Intensive glucose level control vs. Conventional glucose management was evaluated on Infarct size as expressed by the cardiac troponin T level 72 h after admission. The BIOMArCS 2 glucose trial will randomize 300 patients with acute coronary syndrome to intensive or conventional glucose management to assess effects on infarct size.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: